LBLTF (Lattice Biologics) 3-1 Month Momentum %: N/A% (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lattice Biologics 3-1 Month Momentum %?

Lattice Biologics LBLTF -99.00% 3-1 Month Momentum % is N/A% as of Aug. 15, 2026.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-15), Lattice Biologics's 3-1 Month Momentum % is N/A%.

The industry rank for Lattice Biologics's 3-1 Month Momentum % or its related term are showing as below:

LBLTF's 3-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -7.445
* Ranked among companies with meaningful 3-1 Month Momentum % only.

Lattice Biologics  (OTCPK:LBLTF) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Lattice Biologics 3-1 Month Momentum % Related Terms

LBLTF vs ABT, MDT, SYK: 3-1 Month Momentum % Comparison

For the Medical Devices subindustry, Lattice Biologics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lattice Biologics 3-1 Month Momentum % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's 3-1 Month Momentum % falls into.


Lattice Biologics  (OTCPK:LBLTF) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
Lattice Biologics (LBLTF) has a 3-1 Month Momentum % of N/A% as of Aug. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Lattice Biologics and its competitors.
Is Lattice Biologics' 3-1 Month Momentum % too high?
Lattice Biologics' current 3-1 Month Momentum % is N/A%.
How does Lattice Biologics' 3-1 Month Momentum % compare to ABT and MDT?
Lattice Biologics' 3-1 Month Momentum % of N/A% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Lattice Biologics and its competitors. Lattice Biologics's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current 3-1 Month Momentum % is N/A% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.